AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34461058
Drug: Nocturnal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal oxygen therapy (Oxygen, n = 26)
Trial: 34461058
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Air; n = 26)
Trial: 32935460
Drug: Solriamfetol 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 900 mg
Trial: 32719868
Drug: Vadadustat 150
RxNorm normalized name: vadadustat 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat 150 mg
Trial: 32719868
Drug: Vadadustat 300
RxNorm normalized name: vadadustat 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat 300 mg
Trial: 32719868
Drug: Vadadustat 600
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vadadustat 600 mg
Trial: 32719868
Drug: Vadadustat (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat (all doses)
Trial: 35979054
Drug: Esketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (0.5 mg/kg + 2 ml normal saline)
Trial: 35022058
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) combined with routine nursing
Trial: 35443830
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dose of the COMT inhibitor tolcapone
Trial: 34022150
Drug: R-CHOP (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1·4 mg/m2, prednisone 100 mg) every 21 days for up to six cycles
Trial: 34695800
Drug: Mass azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mass azithromycin distribution (specific dosage and duration not mentioned)
Trial: 32717058
Drug: Oral D/L-3-Hydroxybutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D/L-3-Hydroxybutyrate
Trial: 32717058
Drug: Matched intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched intravenous D/L-3-Hydroxybutyrate
Trial: 35830550
Drug: OnabotulinumtoxinA +
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA + hydrogel treatment groups
Trial: 32507146
Drug: TMJ manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMJ manual therapy plus exercise therapy in addition to routine physiotherapy for neck pain (Group B)
Trial: 35393165
Drug: augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: augmentation with aripiprazole for 12 additional weeks
Trial: 35791477
Drug: Post-discharge pharmacist-led
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discharge pharmacist-led follow-up (weekly for 6 months)
Trial: 35791477
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication guidance (control group)
Trial: 32135488
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy with Tegenaria Domestica (domestic house spider)
Trial: 35116067
Drug: Guilingji capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guilingji capsules (GLJC)
Trial: 35116067
Drug: Ginkgo extract
RxNorm normalized name: Ginkgo extract
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo extract tablets
Trial: 33190679
Drug: Levetiracetam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (40 mg/kg)
Trial: 34701328
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy + cisplatin concurrent radiochemotherapy
Trial: 34701328
Drug: PF adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF adjuvant chemotherapy + cisplatin concurrent radiochemotherapy
Trial: 616279865
Drug: NRB-Flush (non-rebreather
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRB-Flush (non-rebreather mask with flush rate oxygen >40 L/min)
Trial: 34131914
Drug: Magnetic seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic seizure therapy (MST)
Trial: 35568246
Drug: Escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose RT (EDRT; 70.2 Gy/39 fractions/5 days a week)
Trial: 35568246
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose RT (SDRT; 55.8 Gy/31 fractions/5 days a week)
Trial: 35568246
Drug: Escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose RT (EDRT)
Trial: 35568246
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose RT (SDRT)
Trial: 33200303
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (S-1 plus cisplatin) followed by D2 gastrectomy plus adjuvant chemotherapy with S-1 (Arm B)
Trial: 33200303
Drug: D2 surgery
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 surgery followed by adjuvant chemotherapy with S-1 (Arm A)
Trial: 32473020
Drug: Hydroxychloroquine sulphate
RxNorm normalized name: Hydroxychloroquine sulphate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulphate 400mg twice daily on Day 1, then 400mg once daily from Day 2 to Day 10
Trial: 93204632
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (3 million units three times weekly)
Trial: 93204632
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (3 million units three times weekly) after prednisolone withdrawal
Trial: 35438151
Drug: Vicagrel 20/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicagrel 20/5 mg (LD/MD)
Trial: 35438151
Drug: Vicagrel 24/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicagrel 24/6 mg
Trial: 35438151
Drug: Vicagrel 30/7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicagrel 30/7.5 mg
Trial: 35438151
Drug: Clopidogrel 300/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300/75 mg
Trial: 32035053
Drug: CaniLeishÂ® vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaniLeishÂ® vaccine, n = 85
Trial: 34223754
Drug: Complex treatment
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex treatment including lymphatic drainage kinesis‐taping and low-frequency pulse magnetic therapy
Trial: 33745865
Drug: Veliparib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (120 mg twice daily) during chemoradiotherapy (CRT)
Trial: 35092305
Drug: KY1005 (0.006,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KY1005 (0.006, 0.018, 0.05, 0.15, 0.45, 1.35, 4, or 12 mg/kg)
Trial: 35092305
Drug: KY1005 (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KY1005 (0.45 mg/kg and above)
Trial: 32741143
Drug: Low-dose Methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Methotrexate (target dose 15-20 mg/week)
Trial: 35923827
Drug: CDP-choline (Rischiaril®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline (Rischiaril® Forte, 1,000 mg of citicoline sodium salt)
Trial: 35923827
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group - CG)
Trial: 33819066
Drug: Budesonide orodispersible
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide orodispersible tablets
Trial: 32048131
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) intravenously for 72 hours (150 mg/kg/h for 1 hour, followed by 12.5 mg/kg/h for 4 hours, followed by 6.25 mg/kg for 67 hours)
Trial: 33587403
Drug: Viloxazine extended-release
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine extended-release (700 mg) + Lisdexamfetamine (50 mg)
Trial: 33587403
Drug: Lisdexamfetamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamfetamine (50 mg)
Trial: 33587403
Drug: Viloxazine extended-release
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine extended-release (700 mg)
Trial: 35063243
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg per day for 24 weeks)
Trial: 35987546
Drug: Telephone-based Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based Behavioral Activation (BA) intervention, eight weekly individual sessions
Trial: 32097450
Drug: Whole-grain rye
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain rye diet (± SDG supplements)
Trial: 35366138
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific therapy (control group)
Trial: 34154965
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of black pepper essential oil
Trial: 36273210
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of strengthening exercises and functional swallowing therapy (group 2)
Trial: 36273210
Drug: Non-invasive brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive brain stimulation added to the combination of strengthening exercises and functional swallowing therapy (group 3)
Trial: 33205809
Drug: Ciraparantag (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag (single IV dose at peak concentrations of the anticoagulant)
Trial: 35859298
Drug: Nano-silymarin (SinaLive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-silymarin (SinaLive soft gel, 70 mg silymarin as nanomicelles, three times daily for two weeks)
Trial: 35859298
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three times daily for two weeks)
Trial: 35534091
Drug: Vita 500
RxNorm normalized name: Vita-Respa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vita 500 (liquid formulation)
Trial: 32804621
Drug: i‐PROACTIF intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i‐PROACTIF intervention (Integrated PRimary care and Occupational therapy for Aging and Chronic disease Treatment to preserve Independence and Functioning)
Trial: 33488071
Drug: BDP/FF/G DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/G DPI (100/6/10µg via DPI, two inhalations twice daily for four weeks)
Trial: 33488071
Drug: BDP/FF/G pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/G pMDI (100/6/10µg via pMDI, two inhalations twice daily for four weeks)
Trial: 33488071
Drug: BDP/FF (100/6µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF (100/6µg via pMDI, two inhalations twice daily for four weeks)
Trial: 34528079
Drug: secukinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab (300 or 150 mg weekly, then 4-weekly thereafter)
Trial: 35313935
Drug: App-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based intervention (HAPPYTEEN) based on Transtheoretical Model (TTM) and Cognitive-Behavioral Therapy (CBT) delivered over 8 sessions for 2 months
Trial: 33991702
Drug: Manipulative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative therapy of sacral torsion
Trial: 32208117
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) transfersomal gel
Trial: 32208117
Drug: Free MB
RxNorm normalized name: Ionosol-MB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free MB gel
Trial: 35315874
Drug: Aspirin (n=565)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (n=565)
Trial: 35315874
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor (n=455)
Trial: 35315874
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet therapy (control; n=529)
Trial: 32556176
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod cream followed by intradermal HBVv (IMQ + ID)
Trial: 32556176
Drug: Topical aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous cream (placebo) followed by intradermal HBVv (AQ + ID)
Trial: 32556176
Drug: Topical aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous cream followed by intramuscular HBVv (AQ + IM)
Trial: 33573341
Drug: iMBI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iMBI plus treatment-as-usual
Trial: 35961614
Drug: Cooking Matters
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooking Matters for Diabetes intervention (6-week program with weekly food provision of 4 servings)
Trial: 35026880
Drug: Habb-e-Asab (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habb-e-Asab (250 mg twice a day for 45 days)
Trial: 35026880
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mg twice a day for 45 days)
Trial: 33961310
Drug: Domagrozumab 5
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 5 mg/kg
Trial: 33961310
Drug: Domagrozumab 20
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 20 mg/kg
Trial: 33961310
Drug: Domagrozumab 40
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 40 mg/kg
Trial: 33961310
Drug: Domagrozumab (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab (after switching from 5 mg/kg to 40 mg/kg)
Trial: 33180565
Drug: SIFT IT
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIFT IT group treatment program (14-week duration)
Trial: 36398695
Drug: Physiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy plus corticosteroid injection (combined), single injection 3-6 days before physiotherapy
Trial: 36384815
Drug: Delivering e‐version
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivering e‐version of oral health education pamphlets to adolescents
Trial: 32877578
Drug: IONIS-PKK-LRx administered
RxNorm normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IONIS-PKK-LRx administered at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months after initial treatment with IONIS-PKKRx for 12 to 16 weeks.
Trial: 32877578
Drug: IONIS-PKKRx administered
RxNorm normalized name: IONIS SOD1Rx
DrugBank: Tofersen (DB14782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IONIS-PKKRx administered weekly subcutaneous injections for 12 to 16 weeks.
Trial: 33176129
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow (NHF) system at 2 kg/L/minute, up to a maximum of 30 L/minute
Trial: 33176129
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula (NC) group at 5 L/minute
Trial: 32459987
Drug: Memory and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memory and learning of treatment contents
Trial: 35367003
Drug: ZyCoV-D vaccine
RxNorm normalized name: ZYCOV-D
DrugBank: ZYCOV-D (DB15892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZyCoV-D vaccine (2 mg per dose, 3 doses administered intradermally via a needle-free injection system 28 days apart)
Trial: 35367003
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 doses administered intradermally via a needle-free injection system 28 days apart)
Trial: 35367003
Drug: ZyCoV-D vaccine
RxNorm normalized name: ZYCOV-D
DrugBank: ZYCOV-D (DB15892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZyCoV-D vaccine
Trial: 34783725
Drug: Paracetamol 1000mg
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000mg
Trial: 35565844
Drug: SAx (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAx (oral supplement containing Hydroxytyrosol and Punicalagin)
Trial: 34863109
Drug: Dexmedetomidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1 μg/kg/hour)
Trial: 32727496
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of ranibizumab (0.5 mg) alone (IVOM-Group)
Trial: 32727496
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of ranibizumab (0.5 mg) with additional micropulse diode laser (IVOM+Laser-Group)
Trial: 35037597
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with nortriptyline
Trial: 32361977
Drug: IMU‐838 (vidofludimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMU‐838 (vidofludimus calcium) single doses (10-40 mg fasting, 10 mg fed)
Trial: 32361977
Drug: IMU‐838 (vidofludimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMU‐838 (vidofludimus calcium) multiple doses (30-50 mg)
Trial: 33542279
Drug: 3‐nitrooxypropanol (3‐NOP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐nitrooxypropanol (3‐NOP), administered daily from birth until three weeks post‐weaning (week 14)
Trial: 32831109
Drug: Bang® Keto
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bang® Keto Coffee (130 kcal, 300 mg caffeine, 20 g protein)
Trial: 32831109
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 kcal, 11 mg caffeine, 1 g protein)
Trial: 35040210
Drug: nano-curcumin 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano-curcumin 240 mg/day for 7 days
Trial: 615917691
Drug: Ranibizumab (RBZ)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (RBZ) 0.3 mg or 0.5 mg monthly injections
Trial: 33047942
Drug: LUCAS 3
RxNorm normalized name: LEUCAS CEPHALOTES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUCAS 3 mechanical CC device
Trial: 35700341
Drug: E2027 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2027 (50 to 400 mg single doses)
Trial: 35700341
Drug: E2027 (≥50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2027 (≥50 mg QD)
Trial: 35700341
Drug: E2027 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2027 (50 mg QD)
Trial: 35700341
Drug: E2027 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2027 (single and multiple administration)
Trial: 34403019
Drug: Hypnotic intervention
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic intervention designed to reduce hot flashes
Trial: 33433656
Drug: Integrative oncology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative oncology treatment program (high adherence, attending ≥4 sessions during the first 6 weeks)
Trial: 33433656
Drug: Integrative oncology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative oncology treatment program (high adherence)
Trial: 33433656
Drug: Integrative oncology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative oncology treatment program (low adherence)
Trial: 32433835
Drug: Aripiprazole Lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole Lauroxil (AL) - AL NanoCrystal Dispersion + oral aripiprazole 30 mg on day 1; AL 1,064 mg on day 8 and every 8 weeks thereafter
Trial: 32433835
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (PP) - PP 234 mg on day 1; PP 156 mg on day 8 and then every 4 weeks thereafter
Trial: 32565073
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg doxycycline administered within 72 hours after tick removal
Trial: 33781979
Drug: Vein of
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein of Marshall ethanol infusion
Trial: 33130933
Drug: Implant Removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant Removal (IR)
Trial: 32829304
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) every 4 weeks (q4wk)